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Introduction
Due to significant research efforts in the field of influenza 
therapy, in the near future we will have a series of new antivirals 
to treat patients with influenza. Most likely, hospitalized 
patients with influenza pneumonia as well as other severe 
forms of influenza will be managed with combination antiviral 
therapy. During the selection of antivirals, it will be important 
for physicians to have a clear understanding of the mechanisms 
of action of anti-influenza medications.
In this manuscript I will review the main steps of the life cycle 
of the influenza virus, classify current and future antivirals 
according to the step that they inhibit in the viral life cycle, and 
summarize antivirals mechanisms of actions. 
Life cycle of influenza virus 
The influenza viruses reach to the human respiratory tract 
via droplets from a patient with active disease. Once in the 
respiratory tract, viruses infect and replicate in epithelial cells. 
The steps in the life cycle of influenza in a human epithelial cell 
are depicted in Figure 1 [1-3]. The influenza virus contains 
three membrane proteins, hemagglutinin, neuraminidase, and 
matrix 2 (M2) protein. Hemagglutinin is the most abundant of 
the three viral proteins, followed by neuraminidase and M2. 
There are eight copies of viral RNA gene segments, viral RNA 
polymerase, and other core proteins inside of the virus (Figure 
1: Influenza virus). 
Step 1. Attachment of influenza virus to epithelial cell
The virus uses the surface glycoprotein hemagglutinin to attach 
to molecules of sialic acids present in the surface of epithelia 
cells (Figure 1: Attachment). Since sialic acids are abundant 
in membranes of human epithelial cells, the virus has multiple 
receptors to attach. The binding of the hemagglutinin to sialic 
acid triggers the next step of viral entry into the cell.
Step 2. Endocytosis of the influenza virus
The virus enters the epithelial cell in an endosome (Figure 1: 
Endocytosis). Inside the endosome, due to the low pH, there is 
a conformational change of the viral hemagglutinin. 
Step 3. Fusion of viral and endosomal membranes
The viral hemagglutinin fuses with the endosomal membrane 
(Figure 1: Fusion). At this point, the viral membrane is in 
contact with the endosomal membrane. 
Step 4. Release of viral components into the cytosol
The low pH in the endosome is responsible for changes occurring 
in the M2 viral membrane protein, with opening of the M2 ion 
channels. As a consequence, the viral core is acidified and the 
viral components are release into the cell’s cytoplasm (Figure 
1: Release). From the cytoplasm, the viral proteins travel to the 
cell’s nucleus. 
Step 5. Transcription and replication of viral RNA
Once in the nucleus, the viral RNA polymerase carries out the 
transcription and replication of the influenza genome (Figure 
1: Replication of viral RNA). Replication of the viral genome 
does not require a primer. 
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Step 6. Transcription and synthesis of viral messenger 
RNA (mRNA)
The virus uses the viral RNA polymerase to generate mRNA 
(Figure 1: Synthesis of viral mRNA). The viral RNA 
polymerase is composed of three protein subunits, the PB2, 
PB1, and PA. During the process of generating viral mRNA, the 
viral RNA polymerase obtains a cap from the cellular mRNA, 
a process called “cap-snatching”. This generates short-capped 
oligomers that will serve as primers for transcription of viral 
mRNA. Once the viral mRNA is formed, it is moved from the 
nucleus to the cytoplasm. 
Step 7. Production of viral proteins
The viral mRNA uses the cell’s ribosomes to translate all viral 
proteins (Figure 1: Production of viral proteins). Some 
proteins will return to the nucleus to form a complex with the 
newly formed viral RNA.  
Step 8. Maturation of viral proteins
Several viral proteins are taken by the Golgi apparatus. As the 
proteins move through the apparatus they mature and become 
ready for assembly (Figure 1: Maturation). 
Step 9. Assembly 
The viral RNA and the new viral proteins accumulate in the 
cytoplasm, and a new virus will be assembled (Figure 1: 
Assembly). The nascent virus will bulge in the cell membrane. 
Step 10. Budding 
During the budding process, the virus will use some of the 
cell’s membrane to form the new viral envelope (Figure 1: 
Budding). The ion channel M2 protein contributes to the 
budding of the virus by functioning as a membrane-bending 
protein. 
Step 11. Release of new viruses
Once the new influenza virus buds from the cell, the virus 
remains attached to the cell’s sialic acid receptor. The viral 
neuraminidase has sialidase activity. By altering sialic acid, the 
neuraminidase is able to release new viruses (Figure 1: Viral 
release).
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Figure 1 Steps of the influenza life cycle in a human epithelial cell E
Antiviral medications to treat influenza
Antiviral medications classified according to the steps that 
they block in the viral life cycle are depicted in Figure 2. The 
mechanisms of action of each antiviral medication and spectrum 
of action against influenza A and B viruses will be reviewed.
Antivirals acting on Step 1: Attachment of influenza 
virus to epithelial cell
Anti-Hemagglutinin Monoclonal Antibodies
Several monoclonal antibodies are being developed which target 
the highly conserved stem region of the hemagglutinin molecule 
of the virus [4]. By blocking the hemagglutinin, the virus is 
not able to attach to the sialic acid receptors. These antibodies 
bind to the more conserved stalk portion of the hemagglutinin 
molecule, and thus, they have broad antiviral activity against 
several influenza A subtypes. Some of the antibodies in clinical 
development include MEDI8852, MHAA4549A, VIS- 410, 
CT-P27, CR6261, and CR8020. There is also in development 
an antibody targeting the hemagglutinin of influenza B 
(MHAB5553A).  
Fludase (DAS181)
Fludase adheres to the membrane of the epithelial cells and 
cleaves the sialic acid from the cell surface [5]. Without sialic 
acid in the cell membrane, the virus has no receptor to attach. 
Fludase is delivered as an aerosolized nebulizer formulation, 
which allows the drug to remove the sialic acid of the epithelial 
cells in the area of infection. Since sialic acid is the human 
receptor for all influenza viruses, the drug has activity against all 
types of influenza viruses. This drug is not approved in the US. 
Antivirals acting on Step 4: Release of viral components 
into the cytosol
Amantadine and Rimantadine 
These drugs block the M2 ion channel protein, inhibiting the 
release of core viral proteins into the cytoplasm. They only block 
M2 ion channel proteins of influenza A viruses. Therefore, these 
medications are not active against influenza B viruses. Due to 
the high levels of resistance to these drugs among the currently 
circulating influenza A viruses, the CDC recommends that 
amantadine and rimantadine not be used in clinical practice [6].
Antivirals acting on Step 5. Transcription and 
replication of viral RNA
Favipiravir
Favipiravir is a potent inhibitor of the viral RNA polymerase 
and block the replication of the influenza viral genome [7]. The 
drug is ribosylated and phosphorylated intracellularly to form 
favipiravir-RTP, which is the active form of the drug. This form 
of the drug is recognized by the viral RNA polymerase and 
incorporated into an emerging viral RNA as a purine which 
results in chain termination during RNA synthesis. Favipiravir 
has a broad spectrum of activity against influenza viruses. 
The spectrum of activity also includes RNA viruses other 
than influenza. Favipiravir has a risk for teratogenicity and 
embryotoxicity. The drug is currently approved for influenza 
infection in Japan but is not approved in the US.
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Figure 2 Classification of antivirals according to the step they inhibit in the influenza life cycle.
Antivirals acting on Step 6: Transcription and synthesis 
of viral mRNA
Baloxavir marboxil 
Baloxavir targets the cap-dependent endonuclease in the PA 
subunit of the viral RNA polymerase and acts by inhibiting 
the process known as cap snatching [8]. This will block the 
production of the primers necessary for transcription of the viral 
mRNA. Baloxavir has activity against Influenza A and B viruses. 
The prodrug baloxavir marboxil is converted by hydrolysis to 
the active form, baloxavir acid. The drug, that is administered as 
a single dose by mouth, was recently approved in the US. 
Pimodivir
Pimodivir targets the PB2 subunit of the viral RNA polymerase 
and acts by preventing the cap-snatching activity of the influenza 
viral polymerase [9]. Pimodivir inhibits the synthesis of viral 
mRNA of influenza A viruses, but is inactive against influenza 
B virus due to structural differences in the PB2 cap-binding 
pocket. This drug is not approved in the US.
Antivirals acting on Step 8: Maturation of viral proteins
Nitazoxanide
Nitazoxanide blocks maturation of the viral glycoprotein 
hemagglutinin [10]. The drug had no effect on the other 
glycoprotein, neuraminidase, or the M2 protein. The drug is 
orally administered and is deacetylated in the blood to the active 
metabolic form tizoxanide. The drug is not approved in the US 
for treatment of influenza.
Antivirals acting on Step 10: Budding of new viruses
Anti-M2 Protein Monoclonal Antibodies
There is an antibody targeting the M2 protein of the influenza 
A virus (TCN032) [11]. The antibody binds to the M2 which is 
exposed during the budding of the new virus on the surface of 
infected cells. The drug prevents virus budding and thus acts by 
a different mechanism from the M2 ion channel inhibitors. This 
drug is not approved in the US.
Antivirals acting on Step 11: Release of new viruses
Oseltamivir, Zanamivir, Peramivir, and Laninamivir
These drugs target the glycoprotein neuraminidase. By 
inhibiting the neuraminidase, they block the detachment of 
the virus from the sialic acid moieties on the epithelial cell. 
Neuraminidase inhibitors have activity against both influenza 
A and B viruses. Oseltamivir, zanamivir, and peramivir are 
approved in the US. Peramivir is an intravenous formulation 
[12]. Laninamivir is approved in Japan but not in the US [13]. 
Conclusions
Our options to treat hospitalized patients with influenza infection 
will continue to expand. Some of the new drugs have improved 
effectiveness compared to currently available drugs when 
treatment is initiated beyond 48 hours after symptom onset. 
Antivirals combinations with drugs which inhibit different steps 
of the influenza life cycle could become the standard approach 
for managing complicated patients. Combination therapy 
may also decrease the risk for the selection of viral resistance. 
Comprehensive understanding of the mechanisms of actions of 
antiviral medications will be necessary when selecting therapy 
for patients hospitalized with severe influenza. 
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